From the Research
Role of CMET in Colon Cancer
- CMET (mesenchymal-epithelial transition) protein expression plays a significant role in the malignant progression of colorectal cancer (CRC) 1.
- The overexpression of cMET is associated with poor clinical outcomes, including shorter overall survival and progression-free survival in patients with CRC 2, 3.
- cMET promotes metastasis and epithelial-mesenchymal transition in colorectal carcinoma by repressing RKIP, a metastasis suppressor 1.
- The MAPK/ERK signaling pathway is implicated in the regulation of cMET and RKIP, and overexpression of cMET can lead to tumor cell invasion, migration, and chemoresistance 1.
Prognostic Significance of cMET
- cMET overexpression is a poor prognostic factor for survival in patients with CRC, with studies showing a significant correlation between cMET expression and overall survival and cancer-related mortality rates 2, 3.
- The expression of cMET is higher in advanced stages of CRC, indicating a worse prognosis and mortality 3.
- cMET-targeted therapy may be a promising strategy for the treatment of CRC, with studies demonstrating the potential of cMET as a therapeutic target for chimeric antigen receptor T (CAR-T) cell therapy 4.
Therapeutic Targeting of cMET
- Molecular targeting of the cMET receptor could be a promising strategy for the treatment of CRC patients, with preclinical evidence supporting the aberrant activation of cMET signaling in CRC 5.
- cMET-targeted CAR-T cells have shown inhibitory effects on colorectal cancer cells in vitro, demonstrating the potential of cMET as a therapeutic target for CAR-T cell therapy 4.
- Further studies are needed to explore the value of cMET-targeted therapy in CRC patients and to characterize the molecular mechanisms of cMET signaling in CRC 2, 5.